Sustiva DMP 266 non-nucleoside reverse transcriptase inhibitor data

DuPont Merck reported findings from Phase III testing of Sustiva, its non-nucleoside RT blocker, at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

Read the full 231 word article

How to gain access

Continue reading with a
two-week free trial.